PRESS RELEASE published on 03/27/2024 at 09:01, 5 months 23 days ago Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Heidelberg Pharma granted orphan drug designation by FDA for its ATAC candidate HDP-101, targeting multiple myeloma. The designation provides significant benefits for the development and potential marketing of the drug FDA Orphan Drug Designation Heidelberg Pharma Multiple Myeloma ATAC Candidate
BRIEF published on 03/25/2024 at 07:15, 5 months 25 days ago Heidelberg Pharma AG présente ses solides performances pour 2023 et ses faits saillants financiers Résultats Financiers 2023 Technologie CAN Heidelberg Pharma SA Essai HDP-101 Thérapie Contre Le Cancer
BRIEF published on 03/25/2024 at 07:15, 5 months 25 days ago Heidelberg Pharma AG Showcases Robust 2023 Performance and Financial Highlights Cancer Therapy Financial Results 2023 ADC Technology Heidelberg Pharma AG HDP-101 Trial
PRESS RELEASE published on 03/25/2024 at 07:10, 5 months 25 days ago Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 Heidelberg Pharma AG announces financial figures and successful business performance in 2023, including efficacy data from HDP-101 clinical trial. New Management Board team and expansion of ADC technology platform Financial Results Business Performance HDP-101 ADC Technology Heidelberg Pharma AG
BRIEF published on 03/19/2024 at 09:52, 6 months ago Heidelberg Pharma reçoit un paiement initial dans le cadre d'un accord de redevances sur les soins de santé Conjugués Anticorps-médicament Heidelberg Pharma Zircaix Redevance En Matière De Soins De Santé Financement Biotechnologique
BRIEF published on 03/19/2024 at 09:52, 6 months ago Heidelberg Pharma Receives Upfront Payment from HealthCare Royalty Agreement Heidelberg Pharma HealthCare Royalty Zircaix Antibody Drug Conjugates Biotech Funding
PRESS RELEASE published on 03/19/2024 at 09:47, 6 months ago Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway Heidelberg Pharma HealthCare Royalty ADC Pipeline Royalty Purchase Agreement Cash Payment
BRIEF published on 03/18/2024 at 07:30, 6 months 1 day ago Heidelberg Pharma passe à la cohorte 6 dans l'étude sur le myélome multiple avec HDP-101 Heidelberg Pharma HDP-101 Myélome Multiple Étude De Phase I/IIa Cohorte 6
BRIEF published on 03/18/2024 at 07:30, 6 months 1 day ago Heidelberg Pharma Advances to Cohort 6 in Multiple Myeloma Study with HDP-101 Heidelberg Pharma HDP-101 Multiple Myeloma Phase I/IIa Study Cohort 6
PRESS RELEASE published on 03/18/2024 at 07:25, 6 months 1 day ago Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study Heidelberg Pharma progresses into Cohort 6 with ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study, showing first objective responses and partial remissions. Amended protocol includes optimized dosing regimens Heidelberg Pharma Multiple Myeloma Phase I/IIa Study ATAC Candidate Protocol Amendment
Published on 09/19/2024 at 23:15, 2 hours 42 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 2 hours 57 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 2 hours 57 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 4 hours 47 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 7 hours 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 7 hours 54 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 8 hours 4 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 8 hours 4 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 8 hours 12 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 8 hours 12 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 8 hours 12 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)